System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ahead of print

PubMed: 41285137 DOI: 10.1016/j.lanmic.2025.101263

Tackling vaccine hyporesponsiveness through global collaboration, diverse population studies, and data integration.

Lancet Microbe

Authors: Abena S Amoah, Selidji T Agnandji, Michel Bengtson, Jennifer A Downs, Meral Esen, Jeevan Giddaluru, Simon P Jochems, Maria M M Kaisar, Julia Makinde, Mikhael D Manurung, Moustapha Mbow, Gemma Moncunill, Rajagopal Murugan, Jacqueline Mutai, Helder I Nakaya, Gyaviira Nkurunungi, Magnus Palmblad, Jeremia J Pyuza, Koen A Stam, Wouter A A de Steenhuijsen Piters, Bridgious Walusimbi, Maria Yazdanbakhsh

Affiliations

  • Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.
  • Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany; Institute of Medical Microbiology, University Hospital Münster, Münster, Germany.
  • Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.
  • Center for Global Health, Weill Cornell Medicine, New York City, NY, USA; Department of Medicine, Weill Bugando School of Medicine, Mwanza, Tanzania.
  • Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany; German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany; Cluster of Excellence EXC 2124: Controlling Microbes to Fight Infections, Tübingen, Germany.
  • Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
  • Master of Biomedicine Programme, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia; Department of Parasitology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
  • Department of Infectious Disease, Faculty of Medicine, Imperial College, London, UK; ManteisBio, London, UK.
  • Department of Immunology, Faculty of Medicine, Pharmacy and Odontology, Cheikh Anta Diop University, Dakar, Senegal; Institute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Dakar, Senegal.
  • ISGlobal, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Barcelona, Spain.
  • Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, USA; Center for Geographic Medicine Research-Coast, Kenya Medical Research Institute, Kilifi, Kenya.
  • Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil.
  • Immunomodulation and Vaccines Group, Vaccine Research Theme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda; Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK.
  • Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands.
  • Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands; Department of Pathology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania; School of Public Health, KCMC University, Moshi, Tanzania.

Abstract

Vaccines have improved global health substantially, preventing millions of deaths worldwide. However, striking variations in the immunogenicity and efficacy of some vaccines persist across populations. Notably, suboptimal responses to some vaccines, also known as vaccine hyporesponsiveness, have been observed in low-income and middle-income countries (LMICs) compared with high-income countries or in rural areas within LMICs compared with urban areas within LMICs. Environmental factors, host genetics, lifestyle, and nutrition contribute to immunological variations influencing vaccine responses, highlighting the need to identify key immune signatures that can be manipulated to overcome vaccine hyporesponsiveness. The integration of diverse datasets, accelerated by artificial intelligence, is essential to achieve this goal, which is currently hampered by the under-representation of data from LMICs. The HypoVax Global knowledge hub aims to address this gap by fostering international collaboration and compiling globally representative immunological data from population studies and vaccine trials. The hub offers a platform for high-dimensional data analyses, promotes equitable partnerships, and strives to ensure that all contributions lead to context-specific insights that can inform immunisation strategies to ultimately overcome vaccine hyporesponsiveness.

MeSH

Vaccines, Income